Clinical Medicine Insights-Oncology is a leading journal published by SAGE Publications Ltd, focusing on the interdisciplinary aspects of oncology. With an open access model since 2007, this journal fosters the dissemination of high-quality research and clinical insights that are crucial for advancing knowledge in cancer treatment and management. Based in New Zealand, it aims to bridge gaps in current oncology practices through the publication of innovative studies, case reports, and reviews. With a respectable ranking in Scopus at #264 out of 404 journals in the oncology category and belonging to the Q3 quartile, it positions itself as a valuable resource for oncologists, researchers, and students committed to enhancing patient outcomes. This journal strives to provide a platform for groundbreaking research that can impact clinical practice and inform policy within the field of oncology.

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

Breast Cancer Management is a pivotal journal in the field of oncology and radiology, published by FUTURE MEDICINE LTD. Since its transition to Open Access in 2018, the journal has aimed to democratize access to cutting-edge research focused on innovative treatments and management strategies for breast cancer. With an ISSN of 1758-1923 and an E-ISSN of 1758-1931, it provides a platform for researchers and clinicians to share findings that enhance patient care and outcomes. The journal has garnered significant attention, placing in the Q3 quartile in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023. Positioned in the United Kingdom, its editorial focus and rigorous peer-review process ensure that it remains at the forefront of breast cancer research. As breast cancer continues to be a major health concern globally, Breast Cancer Management serves as an essential resource for advancing knowledge and fostering collaboration among professionals in this vital area of medicine.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Revista de Senologia y Patologia Mamaria, published by ELSEVIER, serves as a vital resource for researchers and practitioners in the fields of obstetrics, gynecology, oncology, and radiology. With its ISSN 0214-1582 and E-ISSN 1578-1399, the journal's scope encompasses the latest advancements and multidisciplinary approaches to breast pathology and senology. Despite its current Q4 ranking across various categories, the journal continues to contribute significantly to the academic discourse, offering a platform for rigorous peer-reviewed articles, case studies, and clinical trials. Its ongoing commitment to distributing knowledge that advances the field is essential, especially given the increasing relevance of breast health in patient care. Situated in Spain with accessible research from 2012 to 2024, the journal invites contributions that further the understanding and treatment of breast-related diseases, making it an indispensable tool for students and healthcare professionals alike, eager to enhance their expertise in this specialized area.